Celldex Therapeutics
CLDX
27.42
-0.54
-1.93%
Celldex Therapeutics
US · CLDX
#2630 by market cap
Listed 1970
27.42
-0.54
-1.93%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 6 in the most recent period (2026/Q3).
- Total institutional ownership rose 7.2 percentage points.
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 118.54% +7.25pp
- Institutions
- 315 +6
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund77.21%
Hedge Fund28.66%
VC/PE Fund7.52%
Public Company3.06%
Insurance Company0.92%
Private Company0.63%
Government Pension Fund0.51%
Individual/Insider0.24%
Top holders as of 2026-06-30
Wellington Management Group
12.15% · 9.54M sh
FMR
11.00% · 8.64M sh
BlackRock
8.85% · 6.95M sh
Kynam Capital Management, LP
6.78% · 5.32M sh
T. Rowe Price Group, Inc.
5.97% · 4.69M sh
State Street Global Advisors
4.43% · 3.48M sh
Vanguard Capital Management, LLC
4.43% · 3.48M sh
Deep Track Capital, LP
3.74% · 2.94M sh
Logos Global Management, L.P.
2.67% · 2.10M sh
Geode Capital Management, LLC
2.61% · 2.05M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 44 buys · 6 sells
| Name | Role | Stake |
|---|---|---|
| Anthony Marucci | Chief Executive Officer | 0.05% |
| Sam Martin | Senior VP, CFO, Secretary & Treasurer | 0.04% |
| Freddy Jimenez | General Counsel | 0.04% |
| Richard Wright | Former Chief Commercial Officer & Senior VP | 0.03% |
| Ronald Pepin | Chief Business Officer & Senior VP | 0.03% |
| Margo Heath-Chiozzi | Senior Vice President of Regulatory Affairs | 0.02% |
| Elizabeth Crowley | Chief Product Development Officer & Senior VP | 0.01% |
| Tibor Keler | Founder, Chief Scientific Officer & Executive VP | 0.01% |
| Harry Penner | Chairperson | 0.00% |
| Karen Shoos | Former Independent Chair of the Board of Directors | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-24 | Harry Penner | Chairperson | Other Derivative Acquisition | +26,000 | $34.09 |
| 2026-06-24 | Herbert Conrad | Independent Director | Other Derivative Acquisition | +26,000 | $34.09 |
| 2026-06-24 | James Marino | Independent Director | Other Derivative Acquisition | +26,000 | $34.09 |
| 2026-06-24 | Ronald Pepin | Chief Business Officer & Senior VP | Other Derivative Acquisition | +20,000 | $34.09 |
| 2026-06-24 | Anthony Marucci | Chief Executive Officer | Other Derivative Acquisition | +375,000 | $34.09 |
| 2026-06-24 | Tibor Keler | Founder, Chief Scientific Officer & Executive VP | Other Derivative Acquisition | +115,000 | $34.09 |
| 2026-06-24 | Diane Young | Senior VP & Chief Medical Officer | Other Derivative Acquisition | +57,000 | $34.09 |
| 2026-06-24 | Sarah Cavanaugh | Senior Vice President of Corporate Affairs & Administration | Other Derivative Acquisition | +95,000 | $34.09 |
| 2026-06-24 | Garry Neil | Independent Director | Other Derivative Acquisition | +26,000 | $34.09 |
| 2026-06-24 | Keith Brownlie | Independent Director | Other Derivative Acquisition | +26,000 | $34.09 |
| 2026-06-24 | Cheryl Cohen | Independent Director | Other Derivative Acquisition | +26,000 | $34.09 |
| 2026-06-24 | Elizabeth Crowley | Chief Product Development Officer & Senior VP | Other Derivative Acquisition | +100,000 | $34.09 |
| 2026-06-24 | Rita Jain | Independent Director | Other Derivative Acquisition | +26,000 | $34.09 |
| 2026-06-24 | Sam Martin | Senior VP, CFO, Secretary & Treasurer | Other Derivative Acquisition | +93,000 | $34.09 |
| 2026-06-24 | Margo Heath-Chiozzi | Senior Vice President of Regulatory Affairs | Other Derivative Acquisition | +95,000 | $34.09 |
| 2026-06-24 | Denice Torres | Independent Director | Other Derivative Acquisition | +26,000 | $34.09 |
| 2026-06-24 | Freddy Jimenez | General Counsel | Other Derivative Acquisition | +93,000 | $34.09 |
| 2026-06-24 | Teri Lawver | SVP & Chief Commercial Officer | Other Derivative Acquisition | +90,000 | $34.09 |
| 2026-01-01 | Sam Martin | Senior VP, CFO, Secretary & Treasurer | Derivative Exercise and Retained | +4,817 | $10.38 |
| 2025-12-14 | Ronald Pepin | Chief Business Officer & Senior VP | Derivative Exercise and Retained | +19,333 | $2.78–9.02 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Celldex Therapeutics discussion 0 comments